

Impact of Dietary Antigens on Multiple Sclerosis

by

Toohey, L., PhD
Colorado State University Health and Exercise Science USA
ltoo@lamar.colostate.edu

Key words: Dietary antigens; multiple sclerosis, vitamin D, lectins, leaky gut, molecular mimicry

Impact of Dietary Antigens on Multiple Sclerosis

Abstract

Background: Current research provides evidence to support the theory that a diet restricting foods considered to have high antigenic potential might be beneficial in the treatment of MS. Grains, legumes and dairy foods may have high antigenic potential and could be contributing environmental factors in genetically susceptible people.

Design: Literature Review.

Methods: An Internet search of The National Library of Medicine and discussions with colleagues

Results: One of the largest challenges that multiple sclerosis (MS) researchers face today is to find treatments that have positive clinical effects and yet are non-toxic. A host of epidemiological, animal and clinical data supports the theory that manipulation of dietary factors may possess potential for a positive effect upon the progression of MS. Our Paleolithic ancestors did not succumb to degenerative diseases, and MS was non-existent in earlier times. A variety of data indicate that the food proteins and lectins from dairy, gluten, and legumes (found in a Neolithic, or modern diet) can be involved in the activation and expansion of autoreactive T-cells by several mechanisms. These mechanisms vary from direct activation of T-cells and immune components, to indirect activation by increasing intestinal permeability (leaky gut syndrome), peripheral antigenic stimulation, and the propensity for molecular mimicry reactions in genetically susceptible individuals. Molecular mimicry is a process whereby foreign peptides, similar in structure to endogenous peptides, may be working in concert with certain “danger signals” (i.e. lectins) to cause cross reactivity with both foreign and endogenous peptides and thereby break immunological tolerance. In particular, a milk protein (butyrophilin) has now been identified which may be triggering MS due to cross-reactivity, or molecular mimicry, with a myelin protein. Additionally, serum vitamin D levels, which were much higher on the average in our Paleolithic ancestors, are observationally correlated to a reduction in MS lesion activity and may play an important role in the treatment of MS. Administration of vitamin D to animals has resulted in complete regression of the animal model of the disease. A protein in milk, bovine serum albumin) has molecular mimicry with the vitamin D binding protein, and may actually be interfering with vitamin D absorption.

Conclusion: It is theorized that incorporation of a diet which eliminates suspicious dietary elements may hold the potential to reduce the antigenic stimulus (both pathogenic and dietary) and possibly result in a diminution of disease symptoms in certain MS patients. Also, it is proposed that addition of vitamin D to the diet warrants further study to determine efficacy in the treatment of MS. Further research in this area is warranted and well-designed clinical trials are needed to determine the full effect of dietary antigens on multiple sclerosis.

Introduction:

Nutrition. Numerous diets have been proposed to be of benefit for MS (1) but none of these have been rigorously tested under clinical conditions and more importantly none have been supported by an underlying immunological basis. However, there is substantial evidence that indicates a diet regime free of antigenic stimulus may be of benefit in modulating some autoimmune diseases, including MS, by its positive interaction with the immune system (2).

Viral antigens and molecular mimicry. Pathogenic organisms including bacteria and viruses have long been suspected to be involved in the development of autoimmune disease (including MS). Over the past decade, evidence has increasingly suggested that these organisms may elicit certain types of autoimmune disease in genetically susceptible individuals via the process of molecular mimicry (3-6). Wucherpfennig (1995) demonstrated that certain viral peptides, including Epstein Barr virus (EBV), contain an immunodominant sequence of amino acids which not only activates the immune system, but can result in a cross-reactive immune response to myelin basic protein (MBP), which contains similar amino acid sequences (5).

Dietary antigens and molecular mimicry. There is also an emerging body of evidence to indicate that dietary antigens may also serve as an antigenic stimulus in the etiology of autoimmune disease, eliciting a similar cross-reactive immune response with human tissue (7-10). In the case of MS, myelin

oligodendrocyte glycoprotein (MOG) is a myelin autoantigen which is a major target for the autoimmune response in MS and in its animal model Experimental Autoimmune Encephalomyelitis (EAU). Stefferl et al (2000) demonstrated that in EAU, an encephalitogenic T cell response to MOG could either be induced or alternatively suppressed by butyrophilin, a milk protein (11). The researchers also demonstrated that the pathology was mediated by a MHC class II-restricted T cell response that cross-reacts with the MOG peptide sequence 76-87 (IGEGKVALRIQN). Further, there is compelling evidence from both human and animal trials to indicate that dietary glycoproteins (lectins) found in common food stuffs, such as grains and legumes alter intestinal physiology and allow luminal pathogenic antigens access to peripheral tissues. (12-14).

Epidemiological Data

A notable aspect of MS is the distinct variations in disease prevalence throughout the world (15). Genetic susceptibility to MS is well established (16-18), however it would appear that human leukocyte antigen (HLA) haplotype contributes only modestly to overall susceptibility (19, 20) suggesting that the interaction of environmental factors plays a major role in the etiology of MS.

One obvious trend is the increase in MS prevalence in more temperate regions, the so-called north-south gradient (21). There are also smaller scale trends which occur within the same general latitudinal zone. For example, in Canada, MS prevalence in the outports of Newfoundland (~25) is an order of magnitude less than in the rural areas of Alberta (~220) even though genetics and latitude are essentially the same (22, 23). These variations of MS prevalence in areas of genetic and geographical similarity are possibly explained by differences in dietary habits with increased consumption of dairy, gluten and saturated fat correlating with areas of higher MS prevalence (24-26). Fish consumption, on the other hand, is associated with increased intake of vitamin D. A diet low in fish and high in dairy products has been shown by multivariate analysis to be associated with MS prevalence (27). Additionally, fish oil has demonstrated an effect of decreasing the quantity and intensity of the expression of class II MHC molecules on monocytes (28). The Newfoundland/Alberta difference in MS prevalence demonstrates the contrast of this dietary variance: the fishing and vegetable patch food sources of the Newfoundland

outposts as opposed to the cattle ranches and wheat farms of Alberta. Additionally, in Norway, MS prevalence is higher inland and lower on the coast, where fish sources provide omega 3 fatty acids and vitamin D (29). Thus, the epidemiological data is compatible with the hypothesis that Neolithic, agricultural foods may play a role in MS etiology, whereas a diet free of antigenic stimulus and replete in vitamin D may offer protective effects.

MS Pathogenesis

It has been postulated that MS is an autoimmune disease caused by activated T helper-cells which are reactive with one or more proteins in myelin in the CNS. Such potentially autoantigenic proteins include myelin basic protein (MBP), protolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), myelin associated glycoprotein (MAG), heat shock proteins (HSP) and alpha-beta crystallin (30). Furthermore, it is most often interpreted that the autoreactive T-cells are activated in the periphery by foreign antigens (30, 31). The two favored mechanisms for such peripheral activation of myelin sensitive T-cells are by superantigens and by molecular mimicry (31). Little evidence has been offered for the role of superantigens, however numerous studies have provided supporting evidence that molecular mimicry is an effective mechanism for precipitating an autoimmune response (3-6). For example, the Rand et al. study (32) identified a specific IgG antibody which occurred in the CSF of MS patients and which was cross reactive for both a common infectious agent (EBV) and a CNS autoantigen (alpha-beta crystallin). It still remains to be determined exactly which foreign proteins may be mimicking CNS proteins and how and when such foreign proteins engage the immune system such that mimicking reactions **may** occur.

Current data indicate that numerous common viruses and bacteria have the potential to mimic the immuno-dominant epitope of MBP, which many favor as the most likely target of autoaggressive T-cells (5, 6). In the case of butyrophilin, the milk protein, Stefferl et al (2000) believe that their study results identify a mechanism by which the consumption of milk products may modulate the pathogenic autoimmune response to MOG (11). Similar studies have not been done for the other common myelin proteins in the CNS and thus many more potential mimics may exist.

Dietary activation of T cells

If the hypothesis that agricultural food proteins are involved in MS pathogenesis is to be demonstrated, it must be shown that such proteins can play one or more roles in promoting and/or participating in immunological reactions, such as molecular mimicry. A variety of data indicate that the food proteins from dairy, gluten, yeast and legumes can indeed be involved in the activation and expansion of autoreactive T-cells in at least four ways:

1. Agricultural dietary staples such as cereal grains and legumes contain glycoproteins called lectins (e.g. wheat germ agglutinin [WGA], phytohemagglutinin [PHA]). These lectins can promote an overgrowth of gut bacteria such as *Escherichia coli* and *Klebsiella*, which are potential mimics that can initiate an autoimmune reaction against human tissue (12). Such overgrowth of gut bacteria increases the number of potential mimics and the probability of autoimmune involvement.
2. The lectins themselves can also result in substantially increased intestinal permeability (13, 14). Such an increase in intestinal permeability, known to be exhibited by MS patients (33), results in the translocation of pathogenic viruses and bacteria to the periphery (34) where they can participate in molecular mimicry and other immune responses. Such mimicry reactions may involve three way cross reactions between viral antigens, myelin antigens and HLA antigens similar to that hypothesized for rheumatoid arthritis (35, 36).
3. Additionally, dietary lectins from grains and legumes which escape into the periphery have the ability to interact with components of the immune system in a manner which can promote autoimmune reactions. Both WGA and PHA have been shown to rapidly cross the gastrointestinal barrier in a number of animal experiments (37, 38). Phytohemagglutinin has been

demonstrated to promote the expansion of activated T-cell lines (39), to elevate intracellular adhesion molecule (ICAM) expression (40, 41) and to stimulate the production of pro-inflammatory cytokines such as interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF alpha) (42-44). All of these actions would promote previously initiated autoimmune reactions.

4. Finally, dietary antigens have the potential to participate in molecular mimicry of tissue autoantigens and infectious agents. Currently, aside from the work done by Stefferl et al (2000) associating a milk protein with a myelin autoantigen (11), there has been no investigation of molecular similarities between peptides derived from dairy, gluten and legumes with myelin protein epitopes. However similarities between these food peptides and other autoantigens involved in rheumatoid arthritis, uveitis and type 1 diabetes (7-9) as well as infectious agents (EBV) (7) has been established. Additionally, it has also been established that the bovine serum albumin (BSA) protein in milk evokes molecular mimicry with vitamin D binding protein AND complement protein C1q (C1q combines with antigen-antibody complexes and causes lysis of cells and destruction of bacteria/foreign antigens), potentially having an adverse effect on immune regulation (45).

Vitamin D

Vitamin D as immune regulator. Hayes et al. (1997) proposed that a crucial environmental factor in MS was the degree of sunlight exposure catalyzing the production of active vitamin D₃ in skin (unless otherwise specified, vitamin D will herein refer to the biologically active form of vitamin D, 1alpha,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) (46). Further, the researchers hypothesized that vitamin D is a selective immune system regulator inhibiting MS, and suggested that the evidence pointing to vitamin D as a protective environmental factor against MS is circumstantial, but compelling (46).

This hypothesis may explain the striking geographical distribution of MS. Vitamin D production from the sun diminishes as the distance from the equator increases. This would explain the anomaly in Switzerland, where MS prevalence is higher at sea level and lower in the elevation of the mountains,

where ultraviolet light intensity is higher (29, 46). The vitamin D hypothesis would also explain the anomaly in Norway, where MS prevalence is higher inland and lower on the coast, where fish (rich in vitamin D) is consumed at high rates (29, 46)

It has been pointed out that the milk protein BSA affects the immune system by mimicking complement C1q; BSA also mimics vitamin D-binding protein, possibly having implications for reducing serum levels of the vitamin, which in turn would also affect immune status (45). Our Paleolithic ancestors had higher vitamin D levels, probably due to increased sun exposure, and also possibly at least in part due to avoidance of milk, which contains the BSA that mimics vitamin D binding protein, and also possibly due in part to the avoidance of phytate-containing grains, which bind nutrients including vitamin D (47). Vieth (1999) estimates that our ancestors had large intakes of vitamin D, with a naked human in Africa getting at least 10,000 IU a day (48). Nieves et al (1994) studied 80 MS patients and reported that they exhibited low mean levels of 25(OH)D (calcidiol), with a quarter of the subjects presenting with frank vitamin D deficiency (<25nmol/l) (49). It is hypothesized that MS patients spend less time outdoors and receive less sun exposure; it is a known fact that corticosteroids, which are used as a treatment for MS, deplete vitamin D.

To investigate a correlation between lesion activity and fluctuations in vitamin D intake, Embry et al (50) compared published monthly 25(OH)D levels in 415 people, aged 50-80 from southern Germany, along with the data from Auer et al (51). The Auer study demonstrated a strong, near sinusoidal variation in the number of active lesions in 53 MS patients. After taking into consideration a two month lag period, which was a reasonable time period to allow for efficacy of a therapeutic effect of vitamin D, there was a close correspondence, with high levels of 25(OH)D correlating with low levels of lesion activity, and vice versa (50).

Vitamin D as disease modulator: Strong evidence in the animal model demonstrates that: 1.) Vitamin D can completely prevent the development of EAU; 2.) Vitamin D can prevent the progression of EAE when administered at the appearance of the first disability symptoms; 3.) Withdrawal of vitamin D supplementation results in resumption of the progression of EAE; and 4.) A deficiency of vitamin D leads to increased susceptibility to EAE (52;53). Vitamin D has also successfully protected against the

animal models of other diseases, including rheumatoid arthritis (54), lupus (55), and type 1 diabetes (56). Some researchers have offered the stimulation of inflammatory cell apoptosis as a mechanism whereby vitamin D reverses EAE (57).

Mechanisms of immune regulation by vitamin D: There are many aspects of vitamin D which are thought to positively affect immune status. Although it is known that the primary function of vitamin D is the regulation of calcium and phosphorus metabolism, many other characteristics for the vitamin have come to light in recent years, including the inhibition of cancer cell proliferation (58) Of these characteristics, one of the most important functions is inducing Nerve Growth Factor (NGF) (59). Other important functions relating to autoimmune disease are the inhibition of memory T-cells (60), the inhibition of nitric oxide (factor in demyelination) (61), the down-regulation of antigen expression by antigen presenting cells such as macrophages (62), and inhibition of T cell proliferation (63).

Mechanistically, the data point to a role for vitamin D in the development of self-tolerance. “The vitamin D hormone (1,25-dihydroxy vitamin D(3)) regulates T helper cell (Th1) and dendritic cell function while inducing regulatory T-cell function. The net result is a decrease in the Th1-driven autoimmune response and decreased severity of symptoms” (64). Van Halteren et al (2004) report that dendritic cells preconditioned with vitamin D may interfere with ongoing autoimmunity in vivo without affecting T cells with other specificities (65).

The role of fat in immune regulation: The evidence suggests that food-derived peptides, in addition to the viral/bacterial peptides, also have the potential to influence autoimmune reactions, and possibly even mimic myelin protein epitopes. The other aspect of diet which can affect immune reactions is the type and amount of fat (66-68). Notably omega three essential fatty acids (EFAs) which are an important component of nutritional balance (69), have been demonstrated to down-regulate immune responses (68, 70). As mentioned previously, Hughes (1996) demonstrated that fish oil, which is high in omega three EFAs, has demonstrated the ability to specifically down-regulate quantity and intensity of MHC class II molecule expression (28).

Thus dietary proteins from agricultural foods such as dairy, yeast, gluten and legumes theoretically can play a significant role in the currently held model of MS pathogenesis. Furthermore the

replacement of omega three EFAs by agricultural-derived saturated fats and omega six EFAs may well play a subsidiary role. As discussed by Cordain (1999), it would appear that proteins from various foods (e.g. gluten, dairy) result in autoimmune reactions mainly by increasing intestinal permeability and by mimicking infectious and self-antigens (47). Such food-driven autoimmune reactions, although of relatively low magnitude in comparison with infection-driven autoimmune reactions, occur almost on a daily basis and thus have a significant cumulative effect. A diet that eliminates suspected dietary antigens and lectins and focuses on nutrient density-rich foods such as fresh fruits, vegetables, lean meats and fish (which also provides vitamin D), may provide a safe, effective answer for an MS treatment protocol. Clinical trials, however, need to be conducted to prove the theory that a diet low in antigenic stimuli and replete in vitamin D provides protection against the neurological disease of MS.

References

1. Sibley WA. Therapeutic claims in multiple sclerosis. Demos Publications, New York, New York 1992; 202
2. Eaton SB, Konner M. Paleolithic Nutrition: A consideration of its nature and current implications. *New England Journal of Medicine* 1985; 312: 283-289.
3. Davies, JM. Molecular Mimicry: Can epitope mimicry induce autoimmune disease? *Immunology and Cell Biology* 1997; 75: 113-126.
4. Fujinami RS, Oldstone M BA. Amino Acid Homology between the Encephalitogenic Site of Myelin Basic Protein and Virus: Mechanism for Autoimmunity. *Science* 1985; 230: 1043-1045.
5. Wucherpfennig KW. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. *Cell* 1995; 80: 695-705.
6. Talbot PJ, Paquette JS, Ciurli C, et al. Myelin Basic Protein and Human Coronavirus 229E Cross-reactive T-Cells in Multiple Sclerosis. *Annals of Neurology* 1996; 39: 233-240.
7. Ostenstad B, Dybwad A, Lea T, et al., Evidence for monoclonal expansion of synovial T cells bearing V β 2.1/V β 5.5 gene segments and recognizing a synthetic peptide that shares homology with a number of putative autoantigens. *Immunology* 1995; 86: 168-175.
8. Singh VK, Yamaki K, Donoso L. et al. Yeast histone H3-induced experimental autoimmune uveitis. *Journal of Immunology* 1989; 142: 1512-1517.
9. Cavallo MG, Fava D, Monetini L, et al. Cell-mediated immune response to Beta casein in recent-onset insulin-dependent diabetes: implications for disease pathogenesis. *The Lancet* 1996; 348: 926-928.
10. Scott FW. Food-induced Type 1 Diabetes in the BB rat. *Diabetes/Metabolism Reviews* 1996; 12: 341-359.
11. Stefferl, A, Schubart A, Storch M, et al. Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in Experimental Autoimmune Encephalomyelitis. *The Journal of Immunology* 2000; 165: 2859-2865.
12. Banwell JG, Howard R, Kabir I, et al. Bacterial overgrowth by indigenous microflora in the phytohemagglutinin-fed rat. *Can J Microbiol* 1988; 34: 1009-13.
13. Pustzai A. Dietary lectins are metabolic signals for the gut and modulate immune and hormone functions. *Eur J Clin Nutr* 1993; 47: 691-99.
14. Liener IE. Nutritional significance of lectins in the diet In; *The Lectins; Properties, Functions and Applications in Biology and Medicine.* i.E Liener, IJ Goldstein (Eds.) Orlando, Academic Press 1986; 527-552.
15. Kurtzke JF. MS epidemiology worldwide. One view of current status. *Acta. Neurol. Scandin., Supplement* 1995; 161: 23-33.
16. Dyment DA, Sadnovich AD, Ebers GA. Genetics of Multiple Sclerosis. *Human Molecular Genetics* 1997; 6: 1693-1698.

17. Hauser SL, Fleischnick E, Weiner H, et al. Extended major histocompatibility complex haplotypes in patients with multiple sclerosis. *Neurology* 1989; 39: 275-277.
18. Allen M, Sandberg-Wollheim M, Sjogren K, et al. Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. *Human Immunology* 1994; 39: 41-48.
19. Ebers G, Kukay K, Bulman D, et al. A full genome search in multiple sclerosis. *Nature Genetics* 1996; 13: 469-471.
20. Haines J, Pericak-Vance M, Sebonn E. et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. *Nature Genetics* 1996; 13: 477-480.
21. Sadovnick AD, Ebers G. Epidemiology of multiple sclerosis: a critical overview. *Can. Jour. Neur. Sci* 1993; 20: 17-29.
22. Pryse-Phillips WEM. The Incidence and Prevalence of Multiple Sclerosis in Newfoundland and Labrador, 1960-1984. *Annals of Neurology* 1986; 20: 323-328.
23. Svenson LW, Woodhead SE, Platt GH. Regional Variations in the Prevalence Rates of Multiple Sclerosis in the Province of Alberta, Canada. *Neuroepidemiology* 1994; 13: 8-13.
24. Agranoff BW. Diet and the geographical distribution of multiple sclerosis. *Lancet* 1974; 1061-1066.
25. Malosse D, Perron, H, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence, a worldwide study. *Neuroepidemiology* 1992; 11: 304-312.
26. Esparza ML, Sasaki S, Kesteloot H. Nutrition, Latitude and Multiple Sclerosis Mortality: An Ecologic Study. *American Journal of Epidemiology* , 1995; 142: 733-737.
27. Lauer K. The risk of multiple sclerosis in the U.S.A. in relation to sociogeographic features: a factor-analytic study. *J Clin Epidemiol.* 1994 Jan;47(1):43-8.
28. Hughes DA, Pinder AC, Piper Z, et al. Fish oil supplementation inhibits the expression of major histocompatibility complex class II molecules and adhesion molecules on human monocytes. *American Journal Clinical Nutrition* 1996; 63: 267-272.
29. Goldberg P. Multiple Sclerosis: vitamin D and calcium as environmental determinants of prevalence. Part 1: Sunlight, dietary factors and epidemiology. *Intern. J. Environmental Studies* 1974; 6: 19-27.
30. Van Noort JM, Amor S. Cell Biology of Autoimmune Diseases. *International Review of Cytology* 1998; 178: 127-206.
31. Stinissen P, Rans J, Zhang J. Autoimmune Pathogenesis of Multiple Sclerosis: Role of Autoreactive T Lymphocytes and New Immunotherapeutic Strategies. *Critical Reviews in Immunology* 1997; 17: 33-75.
32. Rand KH, Houck H, Denslow ND, et al. Molecular Approach to Find Target(s) for oligoconal bands in Multiple Sclerosis. *J. of Neurol. Neurosurg. Psychiatry* 1977; 65: 48-55.
33. Yacyshyn B, Meddings J, Sadowski D, Bowen-Yacyshyn MB. Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. *Dig Dis & Sci* 1996. 41: 2493-2498.
34. Berg RD. Bacterial translocation from the gastrointestinal tract. *J Med* 1992; 23:217-44.
35. Albani S, Carson DA. A multistep molecular mimicry hypothesis for the pathogenesis of rheumatoid arthritis. *Immunology Today* 1996; 17: 466,470.
36. Baum H, Davies H, Peakman M. Molecular mimicry in the MHC: Hidden clues to autoimmunity? *Immunology Today* 1996; 17: 64-69.
37. Pusztai A, Ewen SWB, Grant G, et al. Antinutritive effects of wheat-germ agglutinin and other N-acetylglucosamine-specific lectins. *Brit J Nutr* 1993; 70:313-21.
38. Pusztai A, Greer F, Grant G. Specific uptake of dietary lectins into the systemic circulation of rats. *Biochem Soc Trans* 1989; 17:527-28.
39. Kawakami K, Yakamoto Y, Onoue K. Effect of wheat germ agglutinin on T lymphocyte activation. *Microbiology and Immunology*, 1988; 32:413-422.
40. Koch AE, Shah MR, Harlow LA, et al. Soluble intercellular adhesion molecule-1 in arthritis. *Clin Immunol Immunopathol* 1994; 71:208-15.
41. Shingu M, Hashimoto M, Nobunaga M, et al. Production of soluble ICAM-1 by mononuclear cells from patients with rheumatoid arthritis. *Inflammation* 1994; 18:23-34.
42. Odeh M. New insights into the pathogenesis and treatment of rheumatoid arthritis. *Clin Immunol Immunopathol* 1997; 83:103-116.
43. van den Bourne BE, Kijkmans BA, de Rooij HH, et al. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. *J Rheumatol* 1997; 24:55-60.
44. Firestein GS, Alvaro-Gracia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. *J Immunol* 1990; 144: 33347-53.

45. PerezMaceda B, Lopez-Bote JP, Langa C, Bernabeu C. Antibodies to dietary antigens in rheumatoid arthritis –possible molecular mimicry mechanism. *Clin Chim Acta* 1991; 203:153-165.
46. Hayes CE, Cantorna MT, DeLuca HF. Vitamin D and multiple sclerosis. *Proc Soc Exp Biol Med* 1997; 216: 21-27.
47. Cordain, L. Cereal Grains: Humanity's Double-edged Sword. *World Review of Nutrition and Dietetics* 1999; 84: 19-73.
48. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. *Am. J. Clin. Nutr.* 1999; 69: 842-856.
49. Nieves J, Cosman F, Herbert J, et al. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. *Neurology* 1994; 44: 1687-92.
50. Embry A F, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. *Ann Neurol* 2000. 48: 271-272.
51. Auer DP, Schumann EM, Kumpfel T, et al. Seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. *Ann Neurol* 2000; 47: 276-277.
52. Cantorna MT, Hayes CE, DeLuca HF. 1,25-Dihydroxyvitamin D₃ reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. *Proc Natl Acad Sci USA* 1996; 93: 7861-7864.
53. VanAmerongen BM, Dijkstra CD, Lips P, et al. Multiple sclerosis and vitamin D: an update. *Eur J Clin Nutr.* Aug 2004; 58(8):1095-109
54. Cantorna, M. Hayes,C, DeLuca, H. 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. *Journal of Nutrition* 1998; 128: 68-72.
55. Lemire J, Ince A, Takashima M. 1,25-dihydroxyvitamin D₃ attenuates the expression of experimental murine lupus of MRL/l mice. *Autoimmunity* 1992; 12: 143-148.
- 56 Mathieu C, van Etten E, Decallonne B, et al. Vitamin D and 1,25-dihydroxyvitamin D₃ as modulators in the immune system. *J Steroid Biochem Mol Biol.* May 2004; 89-90:449-52.
- 57 Spach KM, Pedersen LB, Nashold FE, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D₃ reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. *Physiol Genomics.* 2004 Jul 08; 18:141-51.
- 58 Colston K., Colston M.J, Feldman D. 1,25-Dihydroxyvitamin D₃ and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. *Endocrinology* 1981; 108: 1083-1086.
- 59 Veenstra TD, Fahnstock M, Kumar R. An AP-1 site in the nerve growth factor expression in osteoblasts. *Biochemistry* 1998; 37: 5988-5994.
- 60 Muller K, Bendtzen, K. Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D₃. Different effects on CD45RA⁺ and CD45RO⁺ cells. *Autoimmunity* 1992; 14: 37-43.
- 61 Garcion E. et al. 1,25-dihydroxyvitamin D₃ inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. *Brain Research Molecular Brain Research* 1997; 45: 255-267.
- 62 Nataf S. et al. 1,25-dihydroxyvitamin D₃ exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. *J. Neuro. Exper. Neurol.* 1996; 55: 904-914.
- 63 Yang S, Smith C, DeLuca H. 1 alpha, 25-dihydroxyvitamin D₃ and 19-nor-1 alpha, 25-dihydroxyvitamin D₂ suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. *Biochem. Biophys. Acta* 1993; 1158: 279-286.
- 64 Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. *Exp Biol Med (Maywood).* Dec 2004; 229:1136-42.
- 65 van Halteren AG, Tysma OM, van Etten E, et al. 1alpha,25-dihydroxyvitamin D₃ or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. *J Autoimmun.* Nov 2004; 23(3):233-9.
- 66 Harbige LS. Nutrition and immunity with emphasis on infection and autoimmune disease. *Nutrition and Health* 1996; 10: 285-312.
- 67 Fernandes G, Jolly CA. Nutrition and autoimmune disease. *Nutrition Reviews* 1998; 56: 5162-5169.
- 68 Calder PC. Dietary fatty acids and the immune system. *Nutrition Reviews* 1998; 56: 5170-5183.
- 69 Eaton SB, Eaton SB III, Sinclair AJ, et al. Dietary intake of long-chain polyunsaturated fatty acids during the Paleolithic, in: A.P. Simopoulos (ed.), *The return of omega three fatty acids into the food supply. I. Land-based animal food products and their health effects.* *World Review of Nutrition and Dietetics* 1998; 83: 12-23.
- 70 Miles EA, Calder PC. Modulation of immune function by dietary fatty acids. *Proceedings of the Nutrition Society* 1998; 57: 277-292.